Real-World Evidence Supports Young Adults and Adolescents Taking Pediatric Regimens for Acute Lymphoblastic Leukemia

Servier

Newly-reported real-world evidence (RWE) from Servier shows that adults and adolescents taking asparaginase-based pediatric inspired regimens (PIR) have better outcomes with acute lymphoblastic leukemia than those on non-pediatric treatment plans. The retrospective data, presented at this years American Society of Hematology meeting, comes from claims data of 11,650 patients.

According to , “Overall, this real-world analysis suggests treatment with a PIR leads to higher OS in AYA patients with newly-diagnosed ALL. Patients treated with a PIR (n=187) had a 69% lower risk of death compared to matched patients who received non-PIR (n=187) (hazard ratio [HR]=0.31; 95% confidence interval [CI], 0.18-0.55; log-rank test p-value<0.0001).”

To read more, click here.

(Source: PR Newswire)